KEYMED BIOSCIENCES INC.

Press Releases Keymed Biosciences Inc.

Equities

2162

KYG5252B1023

Market Closed - Hong Kong S.E. Other stock markets 04:08:17 2024-05-17 EDT			5-day change	1st Jan Change
37.65 ^HKD	-1.05%		-3.59%	-23.32%

04-30	Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA	MT
04-29	Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

License agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate, completed	23-03-30	AQ
Keymed Biosciences Announces 2022 Annual Results: Efficiently Promotes Clinical Progress & Proactively Develops Global Strategic Collaboration	23-03-17	PR
AstraZeneca enters license agreement with KYM Biosciences for CMG901, a Claudin-18.2 antibody drug conjugate	23-02-23	AQ
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369	22-08-24	AQ
Keymed has been included as eligible stocks of the Shenzhen-Hong Kong Stock Connect	22-03-07	PR
Keymed Bio Joins Hang Seng Family of Indexes	22-02-18	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW